Aptevo Therapeutics

APVO Lead: Phase 1 ★ Read the deep dive → 3 Biotech Distilled articles ↓

Most recent annual filing: 2026-03-26

Catalyst timeline

Aptevo Therapeutics corporate updateAug 2026Aptevo Therapeutics corporate update, Aug 2026, routine
Mipletamig Ph2 readout1Q 2027Mipletamig Ph2 readout, 1Q 2027, major

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (8 active programs)

mipletamig

APVO436

Protein Target: CD123, CD3

Acute Myeloid Leukemia Phase 1 Phase 1b/2 trial NCT04973618

ALG.APV-527

Protein Target: 4-1BB, 5T4, CD137

Solid Tumors Phase 1 intravenous Alligator Bioscience NCT05934539

APVO603

Protein Target: 4-1BB, OX40

Undisclosed indication Preclinical

APVO442

Protein Target: PSMA, CD3

Prostate Cancer Preclinical

APVO711

Protein Target: PD-L1, CD40

Undisclosed indication Preclinical

APVO455

Protein Target: Nectin-4, CD3

Undisclosed indication Preclinical

APVO451

Protein Target: Nectin-4, CD40, CD3, nectin-4

Solid Tumors Preclinical

APVO452

Protein Target: PSMA, CD40, CD3

Prostate Cancer Preclinical

Technology platforms

ADAPTIR

ADAPTIR protein technology platform for rational design of monospecific and bispecific immunotherapeutic proteins targeting cancer; generates molecules that bind one or more targets with structural and functional advantages over monoclonal antibodies; used to develop clinical and preclinical oncology candidates

Targets: CD3, Nectin-4, PD-L1

ADAPTIR-FLEX

Proprietary flexible multispecific immunotherapy platform enabling adjustable construct design and addition of different therapeutic components; supports development of bispecific and trispecific candidates for solid tumors and hematologic malignancies, including Nectin-4 x PD-L1 backbone applications.

Targets: CD3, Nectin-4, PD-L1

Biotech Distilled coverage (3)

2026-08-15 UPDATE: Aptevo Therapeutics (APVO) - They Just Locked Their Own Piggy Bank 🔒 Paid
2026-08-13 UPDATE: Aptevo Therapeutics (APVO) - The Warrant Treadmill Turns Again 🔒 Paid
2026-06-16 Aptevo Therapeutics (APVO) - Scientific Deep Dive for Mipletamig, ALG.APV-527, and the ADAPTIR Pipeline

Articles open on Substack. Some deep dives are subscriber-only.